Por: Fox Business Business July 25, 2023
Cognition Therapeutics President and CEO Lisa Ricciardi discusses the FDA considering the approval of a new Alzheimer's drug and the progress being made in the space to help combat the disease. Biogen said it expects to eliminate roughly to save money ahead of launching a new drug to treat . Investors are pinning their hopes on Leqembi, as the U.S. biotech company hopes to use the new treatment as a springboard for a return to growth,... + full article
CBS News USA Business July 11, 2023
Medicare last week agreed to cover the new drug Leqembi, the first medication proven to slow the progression of Alzheimer's disease, following the U.S. Food and Drug Administration's of the pricey drug.The decision was by the Alzheimer's Association and others... + más
Medicare rejects Alzheimer's Association request for unrestricted coverage of treatments like Leqembi | CNBC
FDA grants full approval for Alzheimer's drug that has shown to modestly slow cognitive decline | ABC7
ABC7 USA Health July 07, 2023
WASHINGTON -- U.S. officials granted full approval to a closely watched Alzheimer's drug on Thursday, clearing the way for Medicare and other insurance plans to begin covering the treatment for people with the brain-robbing disease.The Food and Drug Administration endorsed... + más
Reimagining Alzheimer’s (Part 4): Cautious Optimism For A New Alzheimer’s Disease Treatment | Forbes
Alzheimer's drug trial shown to slow cognitive decline in long fight against dementia | CNBC
ABC News USA Health July 07, 2023
In a positive step forward for Alzheimer's disease treatment, the Food and Drug Administration on Thursday evening granted full approval for a new drug called .Leqembi is the first drug of its kind with clear evidence it can slow cognitive decline in people with early... + más
What Are the Duties of A Trustee? | Forbes
NBA playoffs 2023: Our insiders dissect the Eastern and Western conference finals | ABC7
Portland Press Herald USA Health July 06, 2023
Vials and packaging for the Alzheimer’s drug Leqembi Eisai via AP WASHINGTON — U.S. officials granted full approval to a closely watched Alzheimer’s drug on Thursday, clearing the way for Medicare and other insurance plans to begin covering the treatment for people with... + más
Alzheimer’s drug Leqembi has full FDA approval now and that means Medicare will pay for it | Los Angeles Times
Alzheimer’s drug Leqembi has full FDA approval now and that means Medicare will pay for it | ABC News
CNBC USA Health February 24, 2023
The Alzheimer's drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023.Eisai via ReutersMedicare will not provide broader coverage of the Alzheimer's drug Leqembi until it receives more evidence that the treatment is reasonable and... + más
Maker of promising Alzheimer's drug Leqembi expects full FDA approval this summer, expanded Medicare coverage | CNBC
Why a new Alzheimer's drug is having a slow US debut | ABC News
CNBC USA Health February 17, 2023
In this articleTek Image/science Photo Library Science Photo Library Getty ImagesJapanese drugmaker expects the Food and Drug Administration to fully approve its Alzheimer's treatment Leqembi this summer, which would expand access to the pricey new antibody under... + más
A new Alzheimer’s drug has been approved. What to know about lecanemab | Orlando Sentinel
Forbes USA Business October 15, 2022
Getty Images Key Takeaways You may have heard the overwhelmingly positive news for Biogen lately—this stock has been a rare winner during a time of extreme volatility in the stock market due to consistent rate hikes. Biogen Inc. (BIBB) is one of the older global biotech... + más
Biogen to pay $900M to settle allegations of improper physician kickbacks | Fox Business
Biogen to pay $900 million to settle allegations it paid doctors kickbacks to prescribe multiple sclerosis drugs | CNBC
About iurex | Privacy Policy | Disclaimer |